Form 4: Celldex Therapeutics SVP & General Counsel Freddy A. Jimenez Reports Stock Option Exercise
SEC Form 4 Filing
Freddy A. Jimenez, SVP & General Counsel of Celldex Therapeutics, exercised stock options and acquired 9,540 shares of common stock on June 5, 2024.
Summary
- On June 5, 2024, Freddy A. Jimenez, the SVP & General Counsel of Celldex Therapeutics, exercised incentive stock options.
- This transaction resulted in the acquisition of 9,540 shares of Celldex Therapeutics common stock at a price of $10.38 per share.
- Following the transaction, Jimenez directly owns 35,464 shares of common stock.
- He also holds 18,454 derivative securities (incentive stock options).
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard insider transaction. It doesn't inherently indicate positive or negative outlook.
Industry Context
This is a routine Form 4 filing, indicating a company insider exercising stock options. It's a common occurrence and provides insight into management's perspective on the company's value.
Stakeholder Impact
- The transaction could have a minor impact on shareholders due to the increase in outstanding shares, but it's unlikely to be significant.
Key Dates
| Date | Description |
|---|---|
| 06/18/2021 | 25% of incentive stock options vested |
| 06/05/2024 | Date of stock option exercise and stock acquisition |
| 06/07/2024 | Date of Form 4 filing |
| 06/18/2030 | Expiration date of incentive stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.